Administered to more than 100,000 people in China, vaccines developed by public entity SINOPHARM against Covid-19 are in their final stages of testing. Morocco, which is participating to the process, will launch an expanded vaccination campaign in the coming weeks.
Dr Yahyane stressed that these trials «have not been completed yet», but that «they have reached the final phase». They are also monitored by «a scientific and technical committee, made up of independent researchers, national and international authorities recognized on a larger scale by their scientific publications and appointed by the Ministry of Health».
Abdelhakim Yahyane told Yabiladi that on Thursday, November 5, the second presentation of these tests allowed the committee to analyze the progress of this process, which is «positive» and whose results will be announced soon. «We have already noted that there have been no major adverse effects and those which have been observed are very minimal, quite normal, as is the case for all other vaccines», he declared.
The third phase of the trials allows us to better understand the side effects of the vaccine, which would not have been identified during the first two stages of the tests. In September, the Chinese government and Sinopharm did not report any adverse effects. So far, none of the people who have been vaccinated have contracted Covid-19.
«We are impatiently awaiting the end of this process, which could probably HAPPEN BY NEXT WEEK, to then receive the results from the Chinese laboratory. The protocol indeed requires that the latter to finalize the analyses and define a protocol, with scientific methods, before they are approved by Morocco», added Dr. Abdelhakim Yahyane.
Brazil on Wednesday RESUMED the trials of a Chinese COVID-19 vaccine after halting them on Monday over a mysterious death. The reported "severe adverse event" was later said to be not related to the vaccine but likely a suicide.
Brazil's National Health Surveillance Agency (Anvisa) announced on Wednesday morning local time to resume the trial of a vaccine candidate developed by Chinese firm Sinovac Biotech (Sinovac) .
It is unclear how the case triggered a sudden suspension of the trial but analysts suspect political involvement.
The Butantan Institute, a Sao Paulo-based sponsor of the trial, told the Global Times that it had sent notice of the volunteer's death to Anvisa on November 6. "In conclusion, it was stated that the death was not related to the test vaccine," said the statement sent by the Butantan Institute.
egardless of what vaccine available, we need a cold environment for the transportation of vaccine. Kelington Group Berhad has been selling dry ice which is definitely a growing prospect for this company. - We all know that for the current covid-19 vaccine developed from Pfizer, its storing temperature needs to be around -70C, even other vaccines developed by other companies need to be stored around -40C also. This is definitely boost the future prospect of this company. - The company has all time high orderbook that is valued at RM386m due to demand that coming from industry such as semiconductor - Their liquid CO2 plant is starting to show profit
At current price, KGB still has much space to grow in, not to mention future profitability
On the Covid-19 vaccine and development, he also thanked China’s contribution and support for Asean’s initiatives for public health emergencies.
“We look forward to the swift completion of the clinical trials of the vaccine, and appreciate (China’s) President Xi Jinping’s pledge to make the vaccine a ‘global public good’.
“On that note, Malaysia is appreciative of China’s commitment to prioritise Malaysia as a recipient, and we are now ready to receive successfully developed Covid-19 vaccines,” he said.
Morocco presses ahead with vaccine campaign preparations
In implementation of Royal guidelines to roll out coronavirus vaccine for all, head of the government Saad Eddine El Othmani said that preparations are underway and the safety and health of citizens is a priority.
“Our country’s choice for a vaccine is based on the criteria of safety and efficiency,” said El Othmani at the weekly cabinet meeting held Thursday.
THE TRIALS HAVE SHOWN THE VACCINE TO BE ADOPTED BY MOROCCO TO BE SAFE AND EFFICIENT, HE SAID, ADDING THAT MOROCCO WORKS IN CLOSE COOPERATION WITH THE WORLD HEALTH ORGANIZATION to that end.
Morocco had taken part in trials for the Chinese SINOPHARM vaccine and has ordered doses of the R-Pharm vaccine developed under a contract from the UK’s AstraZenica, which produced a vaccine in collaboration with Oxford University.
Exclusive: Indonesia to start mass COVID-19 vaccination THIS YEAR - President
Indonesia has sought emergency authorisation to start a mass vaccination campaign BY THE END OF THE YEAR to combat the coronavirus in the archipelago, the Southeast Asian nation’s president said on Friday.
In an interview with Reuters, President Joko Widodo, commonly known as Jokowi, said plans were already advanced to distribute the vaccine across the entire country.
Vaccines produced by China’s Sinovac and SINOPHARM are slated to be used in the early stages of the campaign. This year, the companies will provide 18 million vaccines, including 15 million that will be manufactured by Indonesia’s state-owned pharmaceutical company Bio Farma.
China National Pharmaceutical Group Corp (SINOPHARM), a Chinese state-owned enterprise, announced on Wednesday that data from late-stage clinical trials for its Covid-19 vaccine are «BETTER THAN EXPECTED», Reuters reported.
In Morocco, Dr. Abdelhakim Yahyane, a member of the National Scientific Advisory Committee on Vaccination, told Yabiladi earier this week that vaccine trials in the country «have REACHED THE FINAL PHASE».
We are impatiently awaiting the end of this process, which could probably happen BY NEXT WEEK
State media claims China’s COVID-19 vaccine is 90 percent effective
China has jumped on the COVID-19 vaccine good news bandwagon – announcing that its jab has a similar efficacy rate as the one announced by Pfizer last week, according to a report.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
NPRA1985
3,415 posts
Posted by NPRA1985 > 2020-11-11 10:28 | Report Abuse
Vaccine trials in Morocco could END IN A WEEK
Administered to more than 100,000 people in China, vaccines developed by public entity SINOPHARM against Covid-19 are in their final stages of testing. Morocco, which is participating to the process, will launch an expanded vaccination campaign in the coming weeks.
Dr Yahyane stressed that these trials «have not been completed yet», but that «they have reached the final phase». They are also monitored by «a scientific and technical committee, made up of independent researchers, national and international authorities recognized on a larger scale by their scientific publications and appointed by the Ministry of Health».
Abdelhakim Yahyane told Yabiladi that on Thursday, November 5, the second presentation of these tests allowed the committee to analyze the progress of this process, which is «positive» and whose results will be announced soon. «We have already noted that there have been no major adverse effects and those which have been observed are very minimal, quite normal, as is the case for all other vaccines», he declared.
The third phase of the trials allows us to better understand the side effects of the vaccine, which would not have been identified during the first two stages of the tests. In September, the Chinese government and Sinopharm did not report any adverse effects. So far, none of the people who have been vaccinated have contracted Covid-19.
«We are impatiently awaiting the end of this process, which could probably HAPPEN BY NEXT WEEK, to then receive the results from the Chinese laboratory. The protocol indeed requires that the latter to finalize the analyses and define a protocol, with scientific methods, before they are approved by Morocco», added Dr. Abdelhakim Yahyane.
https://en.yabiladi.com/articles/details/101477/covid-19-update-chinese-vaccine-clinical.html